Covarrubias AJ, et al
Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs
Low circulating levels of IGF-1 in healthy adults are associated with reduced -cell function, increased intramyocellular lipid, and enhanced fat utilization during fasting
Optimal injection timing: First thing in the morning, at least 12 hours after your last meal, and 30-45 minutes before eating breakfast
5-Amino-1MQ Dosage Chart | Quick Breakdown What is 5-Amino-1MQ 5-Amino-1-methylquinolinium (5-amino-1MQ) is a small molecule that is studied for its potential influences on body weight, metabolic health, and possibly cancer progression
Use a new needle and syringe with every injection